AU3651595A - Drug for the prevention and treatment of auto-immune and viral diseases, and diagnostic agents for detecting said diseases - Google Patents
Drug for the prevention and treatment of auto-immune and viral diseases, and diagnostic agents for detecting said diseasesInfo
- Publication number
- AU3651595A AU3651595A AU36515/95A AU3651595A AU3651595A AU 3651595 A AU3651595 A AU 3651595A AU 36515/95 A AU36515/95 A AU 36515/95A AU 3651595 A AU3651595 A AU 3651595A AU 3651595 A AU3651595 A AU 3651595A
- Authority
- AU
- Australia
- Prior art keywords
- diseases
- immune
- auto
- drug
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000010099 disease Diseases 0.000 title 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 2
- 230000001363 autoimmune Effects 0.000 title 1
- 229940039227 diagnostic agent Drugs 0.000 title 1
- 239000000032 diagnostic agent Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 230000003612 virological effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4433708 | 1994-09-21 | ||
DE4433708 | 1994-09-21 | ||
PCT/EP1995/003726 WO1996009395A2 (en) | 1994-09-21 | 1995-09-21 | Drug for the prevention and treatment of auto-immune and viral diseases, and diagnostic agents for detecting said diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
AU3651595A true AU3651595A (en) | 1996-04-09 |
Family
ID=6528818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU36515/95A Abandoned AU3651595A (en) | 1994-09-21 | 1995-09-21 | Drug for the prevention and treatment of auto-immune and viral diseases, and diagnostic agents for detecting said diseases |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3651595A (en) |
WO (1) | WO1996009395A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1573022B1 (en) | 2001-04-10 | 2011-06-08 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 184p1e2 useful in treatment and detection of cancer |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3622221A1 (en) * | 1986-07-02 | 1988-01-14 | Max Planck Gesellschaft | METHOD FOR THE GENE-TECHNOLOGICAL EXTRACTION OF PROTEINS USING GRAM-NEGATIVE HOST CELLS |
DK130889A (en) * | 1989-03-17 | 1990-09-18 | Mogens Kilian | IMMUNOGLOBULIN A1 PROTEASES (IGA1 PROTASES), PROCEDURES FOR GENTECHNOLOGICAL PREPARATION OF SUCH ENZYMES, AND VACCINE-CONTAINING ENZYMES AND SYMBOLS OF PROMISTS OF BACKGROUND IMMUNISTRY AND BIT |
NZ236819A (en) * | 1990-02-03 | 1993-07-27 | Max Planck Gesellschaft | Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions |
DE4140699A1 (en) * | 1991-01-11 | 1992-07-16 | Boehringer Mannheim Gmbh | RECOMBINANT IGA PROTEASE |
WO1992013871A1 (en) * | 1991-01-31 | 1992-08-20 | Washington University | Polypeptides and polynucleotides useful for the diagnosis and treatment of pathogenic neisseria |
ES2127217T3 (en) * | 1991-03-14 | 1999-04-16 | Imclone Systems Inc | RECOMBINATION HYBRID PORINE EPITOPES. |
AU5128493A (en) * | 1992-09-16 | 1994-04-12 | University Of Tennessee Research Corporation, The | Recombinant multivalent m protein vaccine |
-
1995
- 1995-09-21 WO PCT/EP1995/003726 patent/WO1996009395A2/en active Application Filing
- 1995-09-21 AU AU36515/95A patent/AU3651595A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1996009395A3 (en) | 1996-07-18 |
WO1996009395A2 (en) | 1996-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP9700603A3 (en) | Pharmaceutical preparation for the treatment of blood coagulation disorders | |
EP0686203A4 (en) | Compounds and methods for the diagnosis, treatment and prevention of diseases of cell death | |
AU9383098A (en) | Novel targeted contrast agents for diagnostic and therapeutic use | |
EP1029540A3 (en) | Use of droloxifene for the treatment of cardiovascular diseases | |
AU6579498A (en) | Compounds and methods for the diagnosis and treatment of (ehrlichia) infection | |
AU4048295A (en) | Peptide medicaments for the treatment of disease | |
HRP970450B1 (en) | Phenyl-substituted alkenoylguanidides, process for their preparation, their use as drugs or diagnostic agents and drugs containing them | |
AU7060896A (en) | Substituted sulfonimidamides, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them | |
AU2990695A (en) | Mucin-derived proteins for the diagnosis, imaging, and therapy of human cancer | |
HUP0104803A3 (en) | Process and system for the administration of medicine through the skin | |
PL346904A1 (en) | Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas | |
LT96148A (en) | Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction | |
ZA983602B (en) | Use of tetrahydropyridine derivatives for the preparation of drugs for the treatment of diseases which cause demyelination | |
AU2508597A (en) | Drug for the treatment of tumours | |
AU3892593A (en) | Composition for therapeutic or diagnostic use, process for its preparation and its use | |
AU6858996A (en) | Pharmaceutical compositions for the treatment of infectious diseases | |
ZA968990B (en) | Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases. | |
AU3760400A (en) | Methods and reagents for the diagnosis and treatment of multiple sclerosis | |
AU2027495A (en) | Pharmaceutical composition for treating hemorrhoidal diseases | |
AU5053296A (en) | Pharmaceutical agents for the treatment of Alzheimer's disease | |
AU3684395A (en) | Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases | |
AU1820499A (en) | Compounds and methods for the diagnosis and treatment of (b. microti) infection | |
AU3651595A (en) | Drug for the prevention and treatment of auto-immune and viral diseases, and diagnostic agents for detecting said diseases | |
AU4841296A (en) | Diagnosis of and compositions and methods for the treatment of disease | |
AU5611701A (en) | Agent for the diagnosis and therapy of viral diseases |